Simmunome Revenue and Competitors

We address the inefficiency of clinical trial success that is currently at >90% failure rate.\n\nSimmunome is at the leading edge of leveraging AI towards unraveling biological complexity. We transform physiological systems into biologically representative computational models for use in therapeutic and preventative drug discovery. Despite the significant technological advances in biotechnology, high-throughput methods, and computational biology over the last 20 years, it has proven difficult to gain meaningful insights that translate into truly disruptive medicines.\n\nWe combine fragmented data to create holistic models of disease that translate to helping you understand your drug's mechanism of action, increase efficacy in the right target population and predict your drug's safety profile. Ultimately getting you to market faster, reducing your R&D costs, and dramatically increasing your probability of success.